Open Access

RNF213 gene silencing upregulates transforming growth factor β1 expression in bone marrow‑derived mesenchymal stem cells and is involved in the onset of Moyamoya disease

  • Authors:
    • Changshui Wang
    • Cuilian Sun
    • Yueshu Zhao
    • Huimin Song
    • Zhengyou Li
    • Feng Jin
    • Changmeng Cui
  • View Affiliations

  • Published online on: July 15, 2021     https://doi.org/10.3892/etm.2021.10456
  • Article Number: 1024
  • Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Moyamoya disease (MMD) is a chronic and progressive cerebrovascular occlusion disease, the precise etiology of which is poorly understood. Ring finger protein 213 (RNF213) has been previously identified as a susceptibility gene that serves an important role in angiogenesis, where it has been shown to be closely associated with the onset of MMD. Patients with MMD exhibit increased expression levels of various pro‑inflammatory molecules and angiogenic factors. Under certain conditions, bone marrow mesenchymal stem cells (BMSCs) have the ability to differentiate to form neuron‑like and microglia‑like cells. In the present study, a total of 40 MMD patients and 40 healthy individuals were enrolled. ELISA assays revealed that the expression of serum vascular endothelial growth factor (VEGF) and transforming growth factor β1 (TGF‑β1) were higher than that in healthy controls. Furthermore, rat BMSCs (rBMSCs) were isolated and cultured using the whole bone marrow adherence method, which were then phenotyped using flow cytometry. Osteogenic and adipogenic differentiation were determined by using Alizarin red and oil red O staining, respectively. RNF213 was knocked‑down using a lentivirus‑mediated short hairpin RNA system in passage three rBMSCs, and successful transfection of the RNF213 was confirmed by RT‑qPCR and fluorescence imaging. The expression levels of VEGF and TGF‑β1 in these rBMSCs were measured on days 7 and 14, respectively. The results demonstrated that RNF213 knockdown upregulated TGF‑β1 at both protein and mRNA levels, but did not exert any effect on VEGF gene expression. In conclusion, these findings suggested that that RNF213 knockdown may contribute to aberrant TGF‑β1 expression via a pathway that remains to be unidentified, indicating that quantitative changes in RNF213 gene expression may serve an important role in the pathogenesis of MMD.

Related Articles

Journal Cover

September-2021
Volume 22 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang C, Sun C, Zhao Y, Song H, Li Z, Jin F and Cui C: RNF213 gene silencing upregulates transforming growth factor β1 expression in bone marrow‑derived mesenchymal stem cells and is involved in the onset of Moyamoya disease. Exp Ther Med 22: 1024, 2021
APA
Wang, C., Sun, C., Zhao, Y., Song, H., Li, Z., Jin, F., & Cui, C. (2021). RNF213 gene silencing upregulates transforming growth factor β1 expression in bone marrow‑derived mesenchymal stem cells and is involved in the onset of Moyamoya disease. Experimental and Therapeutic Medicine, 22, 1024. https://doi.org/10.3892/etm.2021.10456
MLA
Wang, C., Sun, C., Zhao, Y., Song, H., Li, Z., Jin, F., Cui, C."RNF213 gene silencing upregulates transforming growth factor β1 expression in bone marrow‑derived mesenchymal stem cells and is involved in the onset of Moyamoya disease". Experimental and Therapeutic Medicine 22.3 (2021): 1024.
Chicago
Wang, C., Sun, C., Zhao, Y., Song, H., Li, Z., Jin, F., Cui, C."RNF213 gene silencing upregulates transforming growth factor β1 expression in bone marrow‑derived mesenchymal stem cells and is involved in the onset of Moyamoya disease". Experimental and Therapeutic Medicine 22, no. 3 (2021): 1024. https://doi.org/10.3892/etm.2021.10456